Annexon closed at $4.33 on Nov 4, up 3.34%, 37.8% below its 52-week closing high. Volume of 4.5M shares was 1.25× its 20-day average (close to normal).
Split-adjusted performance: +7.4% over one month, -24.0% over six months, +36.6% over one year.
Short interest was 31.6M shares at the Oct 15 settlement, down 1.2% from the prior report (20.6% of float, 10.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ANNXAnnexon | $4.33 | +3.34% | −24.0% | — | — | — | $820.9M | |
| ABUSArbutus Biopharma | $4.06 | +4.64% | −8.1% | −90.6% | −512.0% | 5.3 | $804.3M | Compare |
| AKTSAktis Oncology | $15.20 | +1.74% | −24.1% | — | −713.5% | — | $845.4M | Compare |
| CYRXCryoPort | $16.70 | +1.52% | +31.6% | +7.7% | −20.9% | — | $845.8M | Compare |
| ALMSAlumis | $6.55 | +0.77% | −74.3% | −37.7% | −8557.2% | — | $847.8M | Compare |
| ARDXArdelyx | $3.29 | +8.58% | −53.7% | +15.7% | −0.6% | — | $849.4M | Compare |
| COLLCollegium Pharmaceutical | $23.67 | −0.25% | −35.2% | +6.3% | −7.5% | 16.1 | $770.6M | Compare |
| CRVSCorvus Pharmaceuticals | $10.57 | +7.53% | −31.6% | — | — | — | $889.2M | Compare |
| ANROAlto Neuroscience | $23.30 | +2.64% | −4.9% | — | — | — | $914.3M | Compare |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
